In a new job - June 2, 2014
Ascendis Pharma appoints new CEO
Danish biotechnology company Ascendis Pharma has appointed Martin Auster, M.D., as Chief Business Officer. Dr. Auster joins the company from United Therapeutics, where he has served as Vice President, Business Development. Prior to United Therapeutics, Dr. Auster held positions in the investment banking industry, including as a Senior Biotechnology Analyst at Wachovia Securities and a Senior Analyst/Healthcare-focused […]
Drug Development Pharma - May 30, 2014
BioInvent sells back to Alligator Bioscience
BioInvent has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum. BioInvent has manufactured ADC-1013 (a FIND optimized n-CoDeR antibody) and the company has announced that it will fulfill the remaining CMC activities required to supply drug product to the First-in-Human study, expected to commence […]
Clinical Trials - May 28, 2014
Adenovir Pharma raises MSEK 10 to complete phase II study and prepare for exit
The Swedish pharmaceutical development company Adenovir Pharma has raised SEK 10 million via a rights issue to fund completion of an ongoing clinical phase II study for treatment of infectious eye disease and to prepare for exit. If successfully developed, drug candidate, APD-209 could become the first effective antiviral treatment of EKC and it could solve […]
Financing - May 28, 2014
Moberg Pharma completes share issue of SEK 60 million
The company has completed a directed share issue of 2.1 million new shares, which brings SEK 60 million to the company before transaction costs. The new share issue, which was resolved by the Board of the company on May 27th, 2014 with authorization from the Annual General Meeting on May 13th, 2014, includes 2,068,965 new […]
Financing - May 27, 2014
Isofol raises SEK 38 million
The capital injection will be used for further clinical development of the company’s drug candidate. Modulfin is currently in phase I/II and is developed to increase the efficacy and decrease side effects during cancer treatments. It is based on a derivative of the B vitamine folic acid. At the moment, Modulfin is tested on cancer […]
In a new job - May 26, 2014
New CEO for Pfizer AB
Malin Parkler will be the new CEO for Pfizer AB. Parkler will assume office in connection with Pfizer’s recent reorganisation. According to Pfizer, Malin Parkler has a wide experience from a number of positions within the company, most recently as business responsible for primary care products. Malin Parkler will succeed the previous CEO Edward Lysen. […]
